BiotechTube
Home/N-Zyme Biotec/Franco Vigile
FV

Franco Vigile

Co-Founder and CEO

N-Zyme Biotec

Therapeutic Areas

GastroenterologyOtolaryngology

N-Zyme Biotec Pipeline

DrugIndicationPhase
Fosamprenavir (Repurposed)Laryngopharyngeal Reflux (LPR)Phase 3
Fosamprenavir SR Oral FormulationLPR / GERDPre-clinical
Fosamprenavir Dry Powder InhalerLPR / Airway RefluxPre-clinical

Leadership Team at N-Zyme Biotec

NJ
Nikki Johnston, Ph.D.
Co-Founder and Chief Scientific Officer
View full N-Zyme Biotec profile